EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic Value of Growth Differentiation Factor-15 in Heart Failure Among Whole Ejection Fraction Phenotypes

Lyu Lyu, Juan Xu, Cui Xv, Hunan Xiao, Zhenzhen Liu, Yanru He, Weiyang Gao, Benchuan Hao, Hongbin Liu iD

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Lyu Lyu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Heart Failure, Stroke Volume, Phenotype. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Special Project of Health Care Fund, Capital Health Research and Development of Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The utility of growth differentiation factor-15 (GDF-15) in predicting long-term adverse outcomes in heart failure (HF) patients is not well established. This study explored the relationship between GDF-15 levels and adverse outcomes in HF patients across various ejection fraction (EF) phenotypes associated with coronary heart disease (CHD) and evaluated the added prognostic value of incorporating GDF-15 into the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score-based model. Methods and results This single-centre cohort study included 823 HF patients, categorized into 230 (27.9%) reduced EF (HFrEF), 271 (32.9%) mid-range EF (HFmrEF), and 322 (39.1%) preserved EF (HFpEF) groups. The median age was 68.0 years (range: 56.0–77.0), and 245 (29.8%) were females. Compared with the HFrEF and HFmrEF groups, the HFpEF group had a higher GDF-15 concentration (P = 0.002) and a higher MAGGIC risk score (P < 0.001). We examined the associations between GDF-15 levels and the risks of all-cause mortality and HF rehospitalization using Cox regression models. The C-index, integrated discrimination improvement (IDI), and net reclassification improvement (NRI) metrics were employed to assess the incremental prognostic value. During the 9.4 year follow-up period, 425 patients died, and 484 were rehospitalized due to HF. Multivariate Cox regression analysis revealed that elevated GDF-15 levels were significantly associated with an increased risk of all-cause mortality [hazard ratio (HR) = 1.36, 95% confidence interval (CI): 1.20–1.54; P < 0.001] and HF rehospitalization (HR = 1.75, 95% CI: 1.57–1.95; P < 0.001) across all HF phenotypes. This association remained significant when GDF-15 was treated as a categorical variable (high GDF-15 group: all-cause death: HR = 1.73, 95% CI: 1.40–2.14; P < 0.001; HF rehospitalization: HR = 3.37, 95% CI: 2.73–4.15; P < 0.001). Inclusion of GDF-15 in the MAGGIC risk score-based model provided additional prognostic value for all HF patients (Δ C-index = 0.021, 95% CI: 0.002–0.041; IDI = 0.011, 95% CI: 0.001–0.025; continuous NRI = 0.489, 95% CI: 0.174–0.629) and HF rehospitalization (Δ C-index = 0.034, 95% CI: 0.005–0.063; IDI = 0.021, 95% CI: 0.007–0.032; continuous NRI = 0.307, 95% CI: 0.147–0.548), particularly in the HFpEF subgroup.

Conclusions

GDF-15 is identified as an independent risk factor for adverse outcomes in HF patients across the entire EF spectrum in the context of CHD. Integrating GDF-15 into the MAGGIC risk score-based model enhances its prognostic capability for adverse outcomes in the general HF population. This incremental prognostic effect was observed specifically in the HFpEF subgroup and not in other subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15Heart FailureStroke VolumePhenotypeBiomarkersHumansFemaleMalePrognosisAgedMiddle AgedFollow-Up StudiesRisk AssessmentSurvival RateVentricular Function, LeftRetrospective Studies

Stichwörter der Autor:innen

Growth differentiation factor‐15Heart failure with mid‐range ejection fractionHeart failure with preserved ejection fractionHeart failure with reduced ejection fractionThe Meta‐Analysis Global Group in Chronic Heart Failure risk score

Substanzen

Growth Differentiation Factor 15BiomarkersGDF15 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, Beijing, China.
  • Medical School of Chinese PLA, Beijing, China.
  • Department of General Surgery, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
  • Department of Medical Administration, The 305 Hospital of PLA, Beijing, China.
  • Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

ORCID-Profile: Hongbin Liu

Förderung

  • Special Project of Health Care Fund
  • Capital Health Research and Development of Special Fund

Zitieren

APA

Lyu, L., Xu, J., Xv, C., Xiao, H., Liu, Z., He, Y., Gao, W., Hao, B., & Liu, H. (2024). Prognostic Value of Growth Differentiation Factor-15 in Heart Failure Among Whole Ejection Fraction Phenotypes. ESC Heart Failure. https://doi.org/10.1002/ehf2.14807

Vancouver

Lyu L, Xu J, Xv C, Xiao H, Liu Z, He Y, et al. Prognostic Value of Growth Differentiation Factor-15 in Heart Failure Among Whole Ejection Fraction Phenotypes. ESC Heart Failure. 2024. doi:10.1002/ehf2.14807

BibTeX
@article{Lyu2024,
  author = {Lyu, Lyu and Xu, Juan and Xv, Cui and Xiao, Hunan and Liu, Zhenzhen and He, Yanru and Gao, Weiyang and Hao, Benchuan and Liu, Hongbin},
  title = {Prognostic Value of Growth Differentiation Factor-15 in Heart Failure Among Whole Ejection Fraction Phenotypes},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14807}
}
Kostenlos starten →